Jul 14, 2023, 07:05
Can an oral, alopecia-free treatment improve outcomes for MBC vs paclitaxel? – Paolo Tarantino
Can an oral, alopecia-free treatment improve outcomes for MBC vs paclitaxel? In METEORA2, just published on JAMA Oncology by Elisabetta Munzone et al, VEX (VNR, endoxan, Xeloda) improved TTF and PFS over paclitaxel, with similar OS and at the cost of G3-4 tox.
https://jamanetwork.com/journals/jamaoncology/fullarticle/2807037
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 20, 2024, 12:34
Nov 20, 2024, 11:34
Nov 20, 2024, 11:23
Nov 20, 2024, 10:18